This finding is consistent with the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), demonstrating that IL-1β blockade with canakinumab after myocardial infarction (MI) reduced the risk of death from CVD, as well as rates of non-fatal AMI and non-fatal stroke. This evidence concerns the gene IL1B and myocardial infarction.